Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients.
about
Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitorsApproved Antiviral Drugs over the Past 50 YearsNew Antiretroviral Treatment for HIVInvestigational reverse transcriptase inhibitors for the treatment of HIV.A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus.Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects.Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study.Cardiovascular risk and dyslipidemia among persons living with HIV: a review.ARVs: the next generation. Going boldly together to new frontiers of HIV treatment.Investigational Antiretroviral Drugs: What is Coming Down the Pipeline.Emerging reverse transcriptase inhibitors for HIV-1 infection.
P2860
Q26777448-AE63DAAA-5A9C-4F4D-AC02-F368FF533D20Q27755387-99B87164-0733-4695-9773-4B6DF5BD7F4EQ28069829-3F798DB3-AE42-4F95-80BB-DBAAFFF35503Q36306231-B5A5F4C1-5BB0-49D1-95B2-77CE4DFD995AQ36692572-FD73A5EB-DCC9-4122-A3A7-A2E74E87C200Q37613039-1B9BEC24-80E6-41A9-A615-6D728CA36778Q37613067-FD4A5774-1107-4A15-9682-91897D3A03BCQ40100018-5F561547-F199-49FE-AC0A-3019AB9FC56FQ43183132-8C7D877F-CE40-49D3-954B-FCE1572D8202Q52566639-3A074CEC-7C8E-4A28-A04E-AF4C0383E3AFQ53686168-866D1CC3-DDAD-4695-AA3E-A6E2877A7E94
P2860
Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Forty-eight-week efficacy and ...... T-naive HIV-positive patients.
@en
type
label
Forty-eight-week efficacy and ...... T-naive HIV-positive patients.
@en
prefLabel
Forty-eight-week efficacy and ...... T-naive HIV-positive patients.
@en
P2093
P356
P1476
Forty-eight-week efficacy and ...... T-naive HIV-positive patients.
@en
P2093
Arasteh Keikawus
Charlotte Harvey
Christian Hoffmann
Debbie P Hagins
Hedy Teppler
Javier O Morales-Ramirez
Josep M Gatell
Melanie Thompson
Olayemi Osiyemi
Robin Dretler
P356
10.7448/IAS.17.4.19532
P433
P577
2014-11-02T00:00:00Z